Showing 4131-4140 of 5771 results for "".
- Vyluma Launches With Myopia Treatment In Phase 3 Developmenthttps://modernod.com/news/vyluma-inc-launches-with-robust-opthalmic-portfolio-leading-with-a-pharmaceutical-treatment-in-phase-iii-for-myopia/2479239/Vyluma announced its establishment as a wholly-owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eye drop to slow the progression of myopia in children. NVK002 is currently in late phase 3
- Study Finds Pfizer, AstraZeneca’s COVID-19 Vaccines “Highly Effective” Against Indian Varianthttps://modernod.com/news/study-finds-pfizer-astrazenecas-covid-19-vaccines-highly-effective-against-indian-variant/2479237/An analysis by Public Health England (PHE) suggests that two doses of COVID-19 vaccines from Pfizer/BioNTech and AstraZeneca are “highly effective” against the B.1.617.2 coronavirus variant first identified in India, the UK government announced on Saturday, according to a FirstWord re
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- Alcon Data Highlights Benefits of Specific AcrySof Modelshttps://modernod.com/news/alcon-data-highlights-benefits-of-specific-acrysof-models/2479232/Alcon has announced the publication of the National Ophthalmology Database (NOD) audit by The Royal College of Ophthalmologists (RCOphth), which collects data on cataract surgery performed in England, Wales and Guerns
- Glaukos Expands its Preserflo MicroShunt Relationship With Santen Via New License Agreementhttps://modernod.com/news/glaukos-expands-its-preserflo-microshunt-relationship-with-santen-via-new-license-agreement/2479228/Glaukos announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical for the Preserflo MicroShunt (development code: DE-128), superseding the previous collaboration and distribution agreements between the two parties. Financial ter
- Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticalshttps://modernod.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/Oxford Finance has announced the closing of a $125 million senior secured term loan with Kala Pharmaceuticals. Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.</
- MedOne Surgical Receives FDA Clearance for its MicroDose Injectorhttps://modernod.com/news/medone-surgical-receives-fda-clearance-for-its-microdose-injector/2479227/MedOne Surgical announced the FDA 510(k) clearance of its MicroDose Injector device for low volume ophthalmic injections into the subretinal space. The pneumatically driven syringe system allows the surgeon to utilize a pneumatic air source, such as a vitrectomy system, to deliver a low volume in
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit
- Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate Nyxol Including for the Treatment of Presbyopiahttps://modernod.com/news/ocuphire-granted-two-new-us-patents-covering-late-stage-drug-candidate-nyxol-including-for-the-treatment-of-presbyopia/2479225/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued two patents covering the company’s late-stage product candidate, Nyxol (phentolamine mesylate). Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Boo
- Roche Receives FDA Authorization for Testing of Asymptomatic People With the Obas SARS-CoV-2 Testhttps://modernod.com/news/roche-receives-fda-authorization-for-testing-of-asymptomatic-people-with-the-obas-sars-cov-2-test/2479223/Roche announced that its cobas SARS-CoV-2 test for use on the widely available, high-throughput cobas 6800/8800 Systems has received Emergency Use Authorization (EUA) from the FDA for testing individuals without symptoms or reasons to suspect COVID-19. This authorization supports the guidance upd